Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808158 | 0.94 | TRPV1 (0.63) | MTNR1ATRPV1FAAHPTGS2 | |
| SCHEMBL3808151 | 0.94 | TRPV1 (0.63) | MTNR1ATRPV1FAAHPTGS2 | |
| SCHEMBL20648088 | 0.88 | MTNR1A (0.70) | MTNR1ATRPV1MEN1KMT2AMTNR1B | |
| SCHEMBL20648004 | 0.87 | MTNR1A (0.69) | MTNR1ATRPV1MEN1KMT2AMTNR1B | |
| SCHEMBL3806274 | 0.82 | MTNR1A (0.62) | MTNR1ATRPV1MEN1KMT2AMTNR1B | |
| SCHEMBL3806536 | 0.81 | MTNR1A (1.00) | MTNR1ATRPV1MEN1KMT2AMTNR1B | |
| SCHEMBL1725354 | 0.81 | MTNR1A (1.00) | MTNR1ATRPV1MEN1KMT2AMTNR1B | |
| SCHEMBL1727281 | 0.81 | MTNR1A (1.00) | MTNR1ATRPV1MEN1KMT2AMTNR1B | |
| SCHEMBL1066221 | 0.81 | MTNR1A (1.00) | MTNR1ATRPV1MEN1KMT2AMTNR1B | |
| SCHEMBL1724741 | 0.81 | MTNR1A (1.00) | MTNR1ATRPV1MEN1KMT2AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | PPP2CA, PPP4C, PPP6C | MTNR1A 1889/4885TRPV1 4687/4885MEN1 3072/4885 |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | PPP2CA, PPP4C, PPP6C | MTNR1A 1889/4885TRPV1 4687/4885MEN1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.